Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuroscientific BiopharmaceuticalsASX:NSB +10.17% Cyclically Adjusted PB Ratio is 1.25 as of Sep. 16, 2026. The stock has 1 warning sign investors should review. Among 680 Biotechnology companies, Neuroscientific Biopharmaceuticals ranks worse than 147058.68% on this metric.
Neuroscientific Biopharmaceuticals (ASX:NSB) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Neuroscientific Biopharmaceuticals Cyclically Adjusted PB Ratio Related Terms
Neuroscientific Biopharmaceuticals Cyclically Adjusted PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuroscientific Biopharmaceuticals Cyclically Adjusted PB Ratio Chart
ASX:NSB vs VRTX, REGN, MRNA: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Neuroscientific Biopharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuroscientific Biopharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuroscientific Biopharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Neuroscientific Biopharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Neuroscientific Biopharmaceuticals Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Neuroscientific Biopharmaceuticals does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.
What does a Cyclically Adjusted PB Ratio of 1.25 mean?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a Cyclically Adjusted PB Ratio of 1.25 as of Sep. 16, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neuroscientific Biopharmaceuticals and its competitors. According to the industry distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 680 companies in the Biotechnology industry.
Is Neuroscientific Biopharmaceuticals' Cyclically Adjusted PB Ratio too high?
Neuroscientific Biopharmaceuticals' current Cyclically Adjusted PB Ratio is 1.25. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.58. Neuroscientific Biopharmaceuticals' value of 1.25 is 20.6% below this industry median. Based on the distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 680 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Neuroscientific Biopharmaceuticals' Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuroscientific Biopharmaceuticals ranks #999999 out of 680 companies for Cyclically Adjusted PB Ratio. This places Neuroscientific Biopharmaceuticals in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.58. Neuroscientific Biopharmaceuticals' value of 1.25 is 20.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.58, based on 680 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuroscientific Biopharmaceuticals's current Cyclically Adjusted PB Ratio of 1.25 is 20.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Neuroscientific Biopharmaceuticals and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuroscientific Biopharmaceuticals's current Cyclically Adjusted PB Ratio is 1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuroscientific Biopharmaceuticals stock overvalued right now?
Neuroscientific Biopharmaceuticals (ASX:NSB) has a current Cyclically Adjusted PB Ratio of 1.25. The current Cyclically Adjusted PB Ratio is 1.25 and 20.6% below the Biotechnology industry median of 1.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Neuroscientific Biopharmaceuticals (ASX:NSB), the current Cyclically Adjusted PB Ratio is 1.25 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Neuroscientific Biopharmaceuticals Ltd is an Australian-based biotechnology company. The company is engaged in the development of diagnostic and treatments for neurodegenerative diseases through preclinical studies of patented technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NSB has been successfully added to your 
